Drug firm Zydus Cadila has received approval from the US health regulator to market an anti-cholesterol drug, Cholestyramine, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market the product, Zydus Cadila said in a statement.
The US is the world's largest drug market and approvals to sell generic medicines there provide companies opportunities to increase their revenue.
Cholestyramine is indicated for the reduction of elevated serum cholesterol.
The product would be manufactured at the company's facility at Baddi in Himachal Pradesh.
The Ahmedabad-based group has now more than 110 approvals from the USFDA.
Disclaimer: No Business Standard Journalist was involved in creation of this content
